-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Lexeo Therapeutics, Raises Price Target to $37

Benzinga·11/16/2026 15:57:22
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and raises the price target from $23 to $37.